Scientific Advisory Board
David Goldblatt is Professor of Vaccinology and Immunology and Head of the Immunobiology Section at the Great Ormond Street Institute of Child Health, University College London (UCL) where he also holds the role of Institute Deputy Director for NHS Engagement. He is a Consultant Paediatric Immunologist at the Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) where he is also Director of Clinical Research and Development. He obtained his medical degree from the University of Cape Town, South Africa, his Paediatric qualifications from the Royal College of Physicians (London) and a PhD in Immunology from the University of London, United Kingdom. He was awarded NIHR Senior Investigator status in 2012, which was renewed in 2016.
He has a long-standing interest in the immune response to vaccines and infectious diseases. He has an active research program studying bacterial conjugate vaccines in the young and the elderly, the ontogeny of the immune response to bacterial carriage and infection, evaluation of functional immunity to S. pneumoniae proteins, the development of new pneumococcal vaccines and the development of functional assays for evaluating immunity to bacterial candidate vaccines including Group A and Group B Streptococcus). He is a regular advisor to the World Health Organization (WHO) on vaccines and is Director of the WHO Reference Laboratory for Pneumococcal Serology based at the UCL Great Ormond Street Institute of Child Health in London as well as co-director of the UCL NIHR Mucosal Pathogen Research Unit (2017-2022). He serves on subcommittees of the United Kingdom Department of Health Joint Committee on Vaccines and Immunisation (JCVI) has advised the US FDA and EMA on vaccine evaluation and has served as a member of MRC, Wellcome Trust and US NIH funding panels.
Dr. William Strohl is founder and owner of BiStro Biotech Consulting LLC, started in 2016 to help biotechnology companies grow and expand their capabilities. Prior to retiring from Johnson & Johnson in 2016, Dr. Strohl was VP and Head, Janssen BioTherapeutics, Janssen R&D, J&J, where he headed up biologics discovery and early development. Before that, Dr. Strohl was head of Biologics Research, the discovery arm of Janssen BioTherapeutics, in which he led the significant improvement of both quantity and quality of development candidates. At J&J, Dr. Strohl and his teams placed more than 30 highly innovative therapeutic proteins into development. Before joining J&J, Dr. Strohl was at Merck and Co from 1997-2008, leading Natural Products Biology, initiating a Microbial Vaccines department, and then later, leading the Biologics discovery efforts, where he was involved in two biotechnology company acquisitions. Dr. Strohl started his career rising from Assistant to Full Professor, Department of Microbiology and Program of Biochemistry, at The Ohio State University, from 1980-1997. Dr. Strohl has over 140 publications and 17 issued patents, has edited two books, and wrote a book entitled „Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharma Industry“ (2012).
James C. Paulson obtained his PhD (Biochemistry) in 1974 from the University of Illinois at Champaign-Urbana, and did post-doctoral work at Duke University Medical Centre, in Durham, North Carolina from 1974-78. From 1978-1990 he rose from Assistant Professor to full Professor and vice-chair in the Department of Biological Chemistry at the UCLA School of Medicine where he developed an interest in analysis of receptor specificity of influenza viruses from different host species. From 1990-1999 he served as Vice President and Member Board of Directors of Cytel Corporation, La Jolla, CA. From 1999-present he has been Professor, in the Departments of Cell and Molecular Biology, Chemical Physiology, and Immunology and Microbial Sciences at The Scripps Research Institute, in La Jolla, California. He served as acting President & CEO from 2014-2015 and is currently Cecil and Ida Green Professor and Chair of Molecular Medicine. His current research interests include the roles of glycan binding proteins in the modulation of immune cell signaling, and the receptor specificity of mammalian and animal influenza viruses.